Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 762

1.

Intensive statin therapy for Indians: Part-I. Benefits.

Enas EA, Pazhoor HC, Kuruvila A, Vijayaraghavan K.

Indian Heart J. 2011 May-Jun;63(3):211-27. Review.

PMID:
22734339
2.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
4.
5.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
6.
7.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review.

PMID:
15358046
8.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. Review.

9.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.

Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.

10.

Optimal medical management of peripheral arterial disease.

Rice TW, Lumsden AB.

Vasc Endovascular Surg. 2006 Aug-Sep;40(4):312-27. Review.

PMID:
16959725
12.

Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.

Natsuaki M, Furukawa Y, Morimoto T, Nakagawa Y, Ono K, Kaburagi S, Inada T, Mitsuoka H, Taniguchi R, Nakano A, Kita T, Sakata R, Kimura T; CREDO-Kyoto PCI/CABG registry cohort-2 investigators.

Circ J. 2012;76(6):1369-79. Epub 2012 Mar 15.

13.
14.

Cholesterol and atherosclerosis: a contemporary perspective.

Kashyap ML.

Ann Acad Med Singapore. 1997 Jul;26(4):517-23. Review.

PMID:
9395824
17.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

18.

Lipid goals in metabolic syndrome and diabetes.

Colhoun HM.

Curr Atheroscler Rep. 2007 Oct;9(4):286-95. Review.

PMID:
18173956
19.

Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.

Pedersen TR.

Am J Cardiovasc Drugs. 2010;10 Suppl 1:10-7. doi: 10.2165/1158822-S0-000000000-00000. Review.

PMID:
21391729
20.
Items per page

Supplemental Content

Write to the Help Desk